Keros Therapeutics KROS posted a dramatic revenue jump in 2025, but the mix matters as much as the magnitude. The shares also trade at a steep discount to book value, creating the classic biotech

Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular dystrophy at the front of the line. The company is positioning the program

In a stunning revelation at its latest annual GTC conference, NVIDIA NVDA CEO Jensen Huang announced that the company now expects to secure up to $1 trillion in chip orders for its next-generation

For investors seeking momentum, Horizon Landmark ETF BENJ is probably on the radar now. The fund just hit a 52-week high and is up 4.4% from its 52-week low price of $50.07 per share.

But are there

Genuine Parts Company GPC, based in Atlanta, is a distributor of automotive and industrial replacement parts and materials. The company operates a vast network of more than 10,800 locations

W&T Offshore, Inc. WTI reported a fourth-quarter 2025 adjusted loss of 14 cents per share, wider than the Zacks Consensus Estimate of a loss of 9 cents. The bottom line improved from the year-ago

Healthpeak Properties, Inc. DOC announced that its pure-play RIDEA-structured senior housing REIT, Janus Living, has launched its initial public offering (IPO) of 37,000,000 shares of its Class A-1

Cencora COR is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.

This Zacks Rank #3 (Hold) company’s